MILANO VINCENT 4

What Happened Vincent Milano, a director of BioCryst Pharmaceuticals, was issued 848 shares of common stock on February 27, 2026 as an award/compensation (transaction code A). The shares were valued at $8.75 each for a total of $7,420. This was an equity award issued in lieu of cash compensation rather than an open‑market purchase or sale.

Key Details

• Transaction date and price: 2026-02-27, 848 shares at $8.75 each (total $7,420).
• Transaction type/code: Award/Grant (A) — equity issued as compensation.
• Footnote: Shares were issued in lieu of 50% of the quarterly cash Board Member retainer ($11,250) and, effective Jan 23, 2026, in lieu of 50% of the quarterly Board Chair retainer ($20,000) (Footnote F1).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Report filed 2026-03-03; appears to be filed on the SEC deadline (timely).

Context This was a compensation issuance (director/board chair retainer converted to stock), which is a routine corporate governance/compensation action and not a market purchase or sale that necessarily signals insider sentiment. For retail investors, purchases by insiders can be more informative; awards and compensation are primarily a form of pay and should be interpreted accordingly.